Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913626 | 0.90 | ALDH1A1 (0.55) | MAPTL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL26239298 | 0.88 | ALDH1A1 (0.58) | MAPTL3MBTL1ALDH1A1ATMTDP1 | |
| SCHEMBL15080869 | 0.88 | CTSK (0.61) | ATMCTSKCTSB | |
| SCHEMBL30946598 | 0.88 | CTSK (0.61) | ATMCTSKCTSB | |
| SCHEMBL29587852 | 0.88 | ALDH1A1 (0.58) | MAPTL3MBTL1ALDH1A1ATMTDP1 | |
| SCHEMBL23056471 | 0.87 | MAPT (0.54) | MAPTL3MBTL1ALDH1A1ATMCTSK | |
| SCHEMBL22692566 | 0.86 | ALDH1A1 (0.58) | MAPTL3MBTL1ALDH1A1NPC1RAB9A | |
| SCHEMBL13296295 | 0.85 | GAA (0.52) | MAPTL3MBTL1ALDH1A1RAB9AATM | |
| SCHEMBL29233276 | 0.85 | ATM (0.51) | MAPTL3MBTL1ALDH1A1ATMCTSK | |
| SCHEMBL10099537 | 0.85 | GAA (0.52) | MAPTL3MBTL1ALDH1A1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| EP-3286174-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172425-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | MAPT 1843/4885L3MBTL1 2230/4885ALDH1A1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.